Annual report pursuant to Section 13 and 15(d)

Annual report pursuant to Section 13 and 15(d)

Consolidated Statements of Operations

v3.6.0.2
Consolidated Statements of Operations - USD ($)
shares in Thousands, $ in Thousands
12 Months Ended
Dec. 31, 2016
Dec. 31, 2015
Dec. 31, 2014
NET REVENUE      
Clinical testing $ 222,015 $ 98,595 $ 86,408
Pharma services 22,068 1,207 661
Total Revenue 244,083 99,802 87,069
Cost of revenue 133,704 56,046 46,355
GROSS MARGIN 110,379 43,756 40,714
Operating expenses:      
General and administrative 75,782 33,631 23,808
Research and development 4,649 4,198 2,689
Sales and marketing 23,910 11,562 11,999
Impairment charges 3,464    
Total operating expenses 107,805 49,391 38,496
INCOME (LOSS) FROM OPERATIONS 2,574 (5,635) 2,218
Interest expense and debt termination fees, net 9,998 854 985
Other income   (2,000) (56)
Income (loss) before taxes (7,424) (4,489) 1,289
Income tax (benefit) expense (1,701) (1,954) 157
NET INCOME (LOSS) (5,723) (2,535) 1,132
Deemed dividends on preferred stock 18,011 40  
Amortization of preferred stock beneficial conversion feature 6,663 82  
NET INCOME (LOSS) ATTRIBUTABLE TO COMMON STOCKHOLDERS $ (30,397) $ (2,657) $ 1,132
NET EARNINGS (LOSS) PER SHARE ATTRIBUTABLE TO COMMON STOCKHOLDERS      
Basic $ (0.39) $ (0.04) $ 0.02
Diluted $ (0.39) $ (0.04) $ 0.02
WEIGHTED AVERAGE COMMON SHARES OUTSTANDING:      
Basic 77,542 60,526 53,483
Diluted 77,542 60,526 56,016